Commentary on opinion pieces re Australian human papillomavirus vaccine policy

Sexual Health

Volumn 7, Issue 3, 2010, Pages 242-243

  McIntyre, Peter ^a  

^a CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

AUSTRALIA; CANCER PREVENTION; COMORBIDITY; CONDYLOMA ACUMINATUM; COST EFFECTIVENESS ANALYSIS; HEALTH CARE POLICY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; IMMUNIZATION; IMMUNOGENICITY; INFECTION PREVENTION; MORBIDITY; NOTE; OUTCOME ASSESSMENT; PAPILLOMATOSIS; PAPILLOMAVIRUS INFECTION; PUBLIC OPINION; QUALITY ADJUSTED LIFE YEAR; RECURRENT RESPIRATORY PAPILLOMATOSIS; SEXUAL HEALTH; UTERINE CERVIX CANCER; VACCINATION; VIRUS IMMUNITY; WART VIRUS;

ADOLESCENT; ADULT; AUSTRALIA; CERVICAL INTRAEPITHELIAL NEOPLASIA; COST-BENEFIT ANALYSIS; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; MASS VACCINATION; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; QUALITY-ADJUSTED LIFE YEARS; SEXUALLY TRANSMITTED DISEASES, VIRAL; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 77956014764     PISSN: 14485028     EISSN: None     Source Type: Journal    
DOI: 10.1071/SH10026     Document Type: Note

References (10)

1. Zhou J, Sun XY, Stenzel DJ, Frazer IH. Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology 1991; 185: 251-257 doi:10.1016/0042- 6822(91)90772-4
2. Beutels P, Scuffham PA, MacIntyre CR. Funding of drugs - do vaccines warrant a different approach? Lancet Infect Dis 2008; 8: 727-733 doi:10.1016/S1473-3099(08)70258-5
3. Brotherton J, Deeks S, Campbell-Lloyd S, Misrachi A, Passaris I, Peterson K, et al. Interim estimates of human papillomavirus vaccination coverage in the school-based program in Australia. Commun Dis Intell 2008; 32: 457-461
4. Fairley CK, Hocking JS, Gurrin LC, Chen MY, Donovan B, Bradshaw CS. Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women. Sex Transm Infect 2009; 85: 499-502. doi:10.1136/sti.2009.037788
5. Stern PL. For debate: that Australia should consider changing to the bivalent vaccine. Sex Health 2010; 7: 238-241 doi:10.1071/SH09131
6. Wain G. For debate: that Australia should continue using the quadrivalent vaccine. Sex Health 2010; 7: 235-237 doi:10.1071/ SH09129
7. Tasca RA, Clarke RW. Recurrent respiratory papillomatosis. Arch Dis Child 2006; 91: 689-691 doi:10.1136/adc.2005.090514
8. Jit M, Choi YH, Edmunds WJ. Economic evaluation of human papillomavirus vaccination in the United Kingdom. BMJ 2008; 337: a769. doi:10.1136/bmj.a769
9. de Kok IMCM, van Ballegooijen M, Habbema JDF. Cost-effectiveness of human papillomavirus vaccination in the Netherlands. J Natl Cancer Inst 2009; 101: 1083-1092 doi:10.1093/jnci/djp183
10. Eggerston L. Two provinces to study two doses of HPV vaccine. Can Med Assoc J 2007; 177: 445-446